Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

L.A. McKeown

July 17, 2023

News Daily News

COVID-19: TCTMD’s Dispatch for February Week 4

Todd Neale

February 21, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Todd Neale

May 04, 2018

News Daily News

Drug for Rare Form of Cardiomyopathy Meets Primary Endpoint in Phase III Trial

Todd Neale

March 30, 2018

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

Shelley Wood

July 20, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Pulmonary Denervation Shows Promise for Resistant Pulmonary Hypertension

Yael L. Maxwell

July 19, 2013

Advertisement

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

ATTRibute-CM Top-Line Results Favorable for Acoramidis

COVID-19: TCTMD’s Dispatch for February Week 4

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Drug for Rare Form of Cardiomyopathy Meets Primary Endpoint in Phase III Trial

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Pulmonary Denervation Shows Promise for Resistant Pulmonary Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content